The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

Novo Nordisk shares jumped nearly 8% on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill, ...

The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...

Today’s Forbes Daily newsletter features the FDA approval of Wegovy pill, gold prices rise again, AI data centers in space, ...

Monday’s approval gives Novo Nordisk a win against GLP-1 competitor Eli Lilly, which manufactures a weight loss injectable ...

Novo Nordisk A/S won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its ...

Here's when you can get the FDA-approved, daily pill version of Novo Nordisk's wildly popular GLP-1 drug Wegovy.

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Novo Nordisk A/S's oral Wegovy wins FDA approval, promising strong 2026 growth with market exclusivity and competitive ...